Current therapies for the treatment of multidrug-resistant tuberculosis in children in India

Mukherjee, Aparna; Lodha, Rakesh; Kabra, S. K.

doi:10.1080/14656566.2017.1373090

Cited by 9 publications

(7 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DR-TB treatment does require a period of at least 9 months plus more drug side effects that occur after the patient has taken the drug, the amount of medicine that must be taken a lot 4 , so assistance here is very much needed to support the continuity of taking medicine, mentoring can be done by the closest person, family, by someone else 11 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Sustainability Approach to Treatment of DR-TB Patients through Community Social Organization (Aisyiyah)

Kusmiati¹,

Agustiyanto²,

Rampengan³

et al. 2020

J Pure Appl Microbiol

View full text Add to dashboard Cite

Multidrug-resistant tuberculosis (MDR-TB) is currently an important public health problem in the world. Treatment of MDR-TB patients takes a long time, 20-24 months in standard regimen or 9-11 months in shorter regimen. Long treatment duration and drug toxicities which higher than drug-sensitive TB can cause drop out of treatment. Aisyiyah is a community social organization which provide assistance to TB patients in order to complete the treatment within specified time period. This study aimed to compare the outcome of DR-TB patients assisted by Aisyiyah and those who did not. A retrospective study was conducted Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Data was taken from DR-TB patients medical record since October 2014 until December 2017. There were 434 MDR-TB patients in the period of October 2014 to December 2017, with 75 patients (17.28%) received assistance from Aisyiyah. The average age was 44.38 ± 12.28 years old. Comparison between those who were assisted and not, from the male sex (49.3% vs 60.2%), women (50.7% vs 39.8%); based on resistance pattern: (5.3% vs 10.3%) from MDR TB, (85.3% vs 75.5%) from RR, (2.7% vs 8.1%) from XDR; Outcome obtained: Cure (1.6% vs 15.0%; p=0,031), Treatment completion (0.0% vs 0.5%; p=0,517), Default (2.8% vs 28.3%; p=0,002); Failed (0.2% vs 1.6%; p=0,718); Death (1.6% vs 7.9%; p=0,965). There were significant correlations between cure and default outcome in DR-TB patients accompanied by Aisyiyah compared to those not accompanied.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The MDR-TB case in Indonesia is estimated to be around 6100 cases each year. The highest percentage of MDR-TB cases was found in Eastern European and Central Asian countries with MDR-TB percentages of 9-32% of new TB cases and 50% of TB cases with a previous history of treatment 4 .…”

Section: Introductionmentioning

confidence: 94%

The Sustainability Approach to Treatment of DR-TB Patients through Community Social Organization (Aisyiyah)

Kusmiati¹,

Agustiyanto²,

Rampengan³

et al. 2020

J Pure Appl Microbiol

View full text Add to dashboard Cite

show abstract

“…Even if they do so, the number of bacilli is not adequate for bacteriological confirmation [ 15 , 77 ]; as a result, diagnosis is often made clinically, especially when there is a history of contact with a DR-TB case [ 78 , 79 ]. Eventually, this causes starting of treatment empirically [ 80 - 82 ]. Moreover, the culture of TB bacilli, the contemporary gold standard diagnostic method [ 83 , 84 ], requires several weeks to months [ 85 ].…”

Section: Reviewmentioning

confidence: 99%

Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now

Chowdhury¹,

Ahmad²,

Sinha³

et al. 2023

Cureus

View full text Add to dashboard Cite

Drug-resistant tuberculosis (DR-TB) has continued to be a global health cataclysm. It is an arduous condition to tackle but is curable with the proper choice of drug and adherence to the drug therapy. WHO has introduced newer drugs with all-oral shorter regimens, but the COVID-19 pandemic has disrupted the achievements and raised the severity. The COVID-19 controlling mechanism is based on social distancing, using face masks, personal protective equipment, medical glove, head shoe cover, face shield, goggles, hand hygiene, and many more. Around the globe, national and international health authorities impose lockdown and movement control orders to ensure social distancing and prevent transmission of COVID-19 infection. Therefore, WHO proposed a TB control program impaired during a pandemic. Children, the most vulnerable group, suffer more from the drug-resistant form and act as the storehouse of future fatal cases. It has dire effects on physical health and hampers their mental health and academic career. Treatment of drug-resistant cases has more success stories in children than adults, but enrollment for treatment has been persistently low in this age group. Despite that, drug-resistant childhood tuberculosis has been neglected, and proper surveillance has not yet been achieved. Insufficient reporting, lack of appropriate screening tools for children, less accessibility to the treatment facility, inadequate awareness, and reduced funding for TB have worsened the situation. All these have resulted in jeopardizing our dream to terminate this deadly condition. So, it is high time to focus on this issue to achieve our Sustainable Development Goals (SDGs), the goal of ending TB by 2030, as planned by WHO. This review explores childhood TB's current position and areas to improve. This review utilized electronic-based data searched through PubMed, Google Scholar, Google Search Engine, Science Direct, and Embase.

show abstract

“…8 For children with suspected benign thymic hyperplasia, classic radiologic features like lobulated thymic contour, Sail sign in chest X ray, clinical profile and age of the child were taken into account to establish the final diagnosis. 9 Sarcoidosis was diagnosed on the basis of increased serum angiotensin converting enzyme (ACE) level, increased urinary calcium-creatinine level, non-caseating granuloma or altered CD4/CD8 ratio in lymph node biopsy or bronchoalveolar lavage fluid. 10 Bacterial or fungal infections were diagnosed by culture or serological tests.…”

Section: Benign Mediastinal Massesmentioning

confidence: 99%

Comparison of Benign and Malignant Mediastinal Masses in Children-Clinical Features, Etiology and Treatment Outcome: a Prospective Observational Study

Panda

2019

Pediatric Oncall

View full text Add to dashboard Cite

Introduction: Mediastinal masses in children pose a diagnostic as well as therapeutic dilemma to clinicians. There is paucity of information in existing literature regarding relative prevalence of various etiologies and their management outcomes in children. Methods:In this single institution observational prospective studycarried out between August 2013 and July 2017, 86 children with mediastinal masses were evaluated for the etiology, clinical features and treatment outcomes. Prevalence of superior mediastinal syndrome (SMS), factors associated with its occurrence and its clinical implications were also determined.Results: Out of 86 children with mediastinal masses, 28 (32%) had benign masses and 58 (68%) had malignant masses. Tuberculosis (TB) was the commonest among benign mediastinal mass seen in 22 (79%) children. Among the common malignant masses, Hodgkin's lymphoma was seen in 16 (27%), T cell acute lymphoblastic leukemiawas seen in 14 (24%) and neurogenic tumors were seen in 8 (13%) children. SMS was present in 40 (45%) children. SMS was present in 8 (24%) patients with T cell acute leukemia (p=0.01). Solid tumors in advanced stage i.e. stage III and IV were more likely to have SMS (odds ratio 2.7, p=0.29). The overall progression free survival was 76% and 97% for malignant and benign mediastinal masses respectively at the end of median follow up period of 24 months (p=0.01). The subgroup with superior mediastinal syndrome had relatively acute presentation and poor final outcome. Conclusion:In children, malignant mediastinal masses are more common than benign mediastinal masses and they have relatively poor prognosis. Hodgkin's lymphoma and TB are the most common cause of malignant and benign mediastinal masses in children respectively. T cell leukemia is the most common cause of SMS. The prognosis was comparatively dismal for the subgroup with SMS.

show abstract

Current therapies for the treatment of multidrug-resistant tuberculosis in children in India

Cited by 9 publications

References 68 publications

The Sustainability Approach to Treatment of DR-TB Patients through Community Social Organization (Aisyiyah)

The Sustainability Approach to Treatment of DR-TB Patients through Community Social Organization (Aisyiyah)

Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now

Comparison of Benign and Malignant Mediastinal Masses in Children-Clinical Features, Etiology and Treatment Outcome: a Prospective Observational Study

Contact Info

Product

Resources

About